VOI
16.3.2020 08:02:10 CET | Business Wire | Press release
Micromobility. Moving Cities into a Sustainable Future finds that Voi has reduced emissions by 71% over a year on e-scooters used in Paris by introducing best-practice measures and a new scooter model with a swappable battery.
- Voi’s Paris scooters now produce 35g CO2 equivalents per person per kilometre, on par with many public transport options
- Swappable battery scooters and cargo bike operations helped achieve a 51% reduction in emissions
- Voiager 3 - the latest Voi model with a swappable battery - is expected to have a 24 month lifespan
- The average emission level of new cars in the EU is 120.4g CO2/km
The report also finds that:
- E-scooters are being taken up at 4 x the rate of e-bikes
- There are over 20 million users of e-scooters across Europe
- E-scooters have accumulated over 300 million trips globally in two years
- Since launched in California in September 2017, e-scooters have reached 626 cities across 53 countries
- 63% of Voi’s users have combined e-scooters with public transport
Please see below a statement from Voi’s co-founder and CEO Fredrik Hjelm to go with the EY report and a link to the report Micromobility. Moving Cities into a Sustainable Future here .
“Fundamental to Voi’s mission has been our belief that e-scooters and micro mobility can transform the way that people live, work and move through cities. We are delighted to see that EY also recognises the huge benefits that e-scooters could bring to cities and their potential to transform mobility options. In particular we are proud that our efforts to reduce emissions from our Paris operations have demonstrated that e-scooters can be just as sustainable an option as public transport, and produce a fraction of the emissions of new cars. Using insight from real-world data and interviews with city officials, this report shows how e-scooters are making the biggest impact, and where work still needs to be done.”
“We're under no illusion that e-scooters are the silver bullet when it comes to sustainable cities. Nevertheless the improvements we have made to our fleet and the supply chain are already shifting the dial. We very much welcome the report’s conclusion that e-scooters offer unprecedented potential but only when there are clear regulations that foster responsible and sustainable behaviour."
John Simlett, EY’s Global Future of Mobility Leader, says:
“Micromobility is here to stay, reducing emissions as well as relieving pressure on public transport systems, but cities and providers need to work together to seize this opportunity.
“In order to ensure that it takes its rightful place in the urban mobility ecosystem of tomorrow, the next phase of development in micromobility needs to be handled in a more collaborative, integrated and responsible way. This will require clear regulations on responsible and sustainable use, and increasing public access to micromobility infrastructure.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005109/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
